Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency

Journal of Tropical Pediatrics

Volumn 51, Issue 3, 2005, Pages 194-195

  Kilic, Sara Sebnem ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DEMYELINATION; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG INFUSION REACTION; ELBOW DISEASE; FEVER; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; IMMUNOLOGICAL PARAMETERS; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KNEE ARTHRITIS; KNEE PAIN; LABORATORY TEST; LETTER; MALE; MALIGNANT NEOPLASTIC DISEASE; PHYSICAL EXAMINATION; SCHOOL CHILD; SPLENOMEGALY; TREATMENT OUTCOME; TUBERCULOSIS; ARTICLE; CHILD; DOSE RESPONSE; DRUG ADMINISTRATION; HOSPITALIZATION; IMMUNOLOGY; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 23944526940     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmi027     Document Type: Letter

References (8)

1. Conley ME, Park CL, Douglas SD. Childhood common variable immunodeficiency with autoimmune disease. J Pediatr 1986; 108: 915-22.
2. Moreland LW. The role of cytokines in rheumatoid arthritis: Inhibition of cytokines in therapeutic trials. Drugs Today 1999; 35: 309-19.
3. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003; 12: 1087 95.
4. Burgos-Vargas R, Rudwaleit M, Sieper J. The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. Rheumatology (Oxford) 2002; 41: 1183-89.
5. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. Br J Dermatol 2001; 144: 597-600.
6. Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child 2003; 88: 186-91.
7. Oster AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329 (7477): 1266.
8. St Clair EW. Infliximab treatment for rheumatic disease: Clinical and radiological efficacy. Ann Rheum Dis 2002; 61 (Suppl II): 67-9.